Study: A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Treatment Trial
Clinical Trial #: MM1OA-EA02
NCT #: NCT06317649
Principal Investigator: Jessica Altman, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: First-in-Human Phase I and II Study to Determine Safety and Efficacy of Proton-Spatially Fractionated Radiotherapy (P-SFRT) in Retroperitoneal Soft Tissue Sarcoma
Clinical Trial #: NU 23S01
NCT #: NCT06327477
Principal Investigator: Dr. Pollack
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Randomized Phase III Trial of Doxorubicin + Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas
Clinical Trial #: EA7222
NCT#: NCT06422806
Principal Investigator: Seth M. Pollack, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A randomized phase II study of CHO(E)P vs CC-486-CHO(E)P vs duvelisib-CHO(E)P in previously untreated CD30 negative peripheral T-cell lymphomas
Clinical Trial #: A051902
NCT#: NCT04803201
Principal Investigator: Jonathan Moreira, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase II/III Randomized Study of R-MiniCHOP with or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC AND BCL2 and/or BCL6 Rearrangements
Clinical Trial #: S1918
NCT#: NCT04799275
Principal Investigator: Reem Karmali, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Randomized Phase 3 trial of Nivolumab(NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma
Clinical Trial #: COG ANHL1931 NU
NCT#: NCT04759586
Principal Investigator: Reem Karmali, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study
Clinical Trial #: S1925
NCT Number: NCT04269902
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase II multi-center open-label trial of six doses of pembrolizumab monotherapy prior to limited chemotherapy as front-line therapy for patients with classical Hodgkin lymphoma, including elderly patients
Clinical Trial #: NU 23H06
NCT #: NCT06164275
Principal Investigator: Dr. Winter
Contact: Research Office 630.933.7820

Study: A phase 1/1b adaptive dose escalation study of mycophenolate mofetil (MMF) in combination with standard of care for patients with glioblastoma
Clinical Trial #: NU 21C01
NCT#: NCT05236036
Principal Investigator: Priya Kumthekar, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Clinical Trial #: NRG-BN012
NCT#: NCT05438212
Principal Investigator: Dr. Magill
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Safety and tolerability of MW151 administered with hippocampal avoidant whole brain radiation therapy (HA-WBRT) in patients with brain metastases
Clinical Trial #: MW151-102 ImmunoChem
NCT#: NCT05417282
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
Clinical Trial #: NRG-CC009
Principal Investigator: Dr. Sachdev
Contact: Research Office 630.933.7820

Study: A Phase 2, single arm, open label trial Combining Optune with concurrent Bevacizumab in the setting of Recurrent or Progressive Meningioma
Clinical Trial #: NU 16C02
NCT#: NCT02847559
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase I study of Safety and Tolerability of Acetazolamide with Temozolomide in Adults with Newly Diagnosed MGMT Promoter-Methylated Malignant Glioma
Clinical Trial #: 18-048 BrainUp
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Study: Phase III Trial of Observation versus Irradiation for a Gross Totally Resected Grade II Meningioma
Clinical Trial #: NRG-BN003
NCT #: NCT03180268
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov²

Study: Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations
Clinical Trial #: A071401
NCT #: NCT02523014
Principal Investigator: Dr. Gondi
Contact: Research Office 630.933.7820

Study: Genomically-Guided Treatment Trial in Brain Metastases
Clinical Trial #: A071701
NCT #: NCT03994796
Principal Investigator: Dr. Kumthekar
Contact: Research Office 630.933.7820

Study: Cognitive Training For Cancer Related Cognitive Impairment In Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
Clinical Trial #: NRG CC011
NCT#: NCT05896189
Principal Investigator: Regina Stein, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Clinical Trial #: A012103
NCT#: NCT05812807
Prinicpal Investigator: Dr. Tellez
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) Plus Chemotherapy Versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Clinical Trial #: S2206
NCT #: NCT06058377
Prinicpal Investigator: Dr. Tellez
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)
Clinical Trial #: NRG BR009
NCT #: NCT05879926
Principal Investigator: Dr. Lu
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Clinical Trial #: S2007
NCT #: NCT04647916
Prinicipal Investigator: Dr. Tellez
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
Clinical Trial #: S2212
NCT #: NCT05929768
Principal Investigator: Dr. Flaum
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO*) *Her2 Radiation Optimization (HERO)
Clinical Trial #: NRG-BR008
NCT #: NCT05705401
Principal Investigator: Eric Donnelly, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase III Clinical Trial Evaluating De-escalation Of Breast Radiation For Conservative Treatment Of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score = 18 Breast Cancer (DEBRA)
Clinical Trial #: NRG-BR007
NCT #: NCT04852887
Principal Investigator: Dr. Donnelly
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Clinical Trial #: S2007
NCT#: NCT04647916
Principal Investigator: Dr. Ami Shah
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Clinical Trial #: A011801 22-011
NCT#: NCT04457596
Principal Investigator: Dr. Ayers
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: PRAGMATIC PHASE III RANDOMIZED TRIAL OF PROTON VS. PHOTON THERAPY FOR PATIENTS WITH NON-METASTATIC BREAST CANCER RECEIVING COMPREHENSIVE NODAL RADIATION: A RADIOTHERAPY COMPARATIVE EFFECTIVENESS (RADCOMP) CONSORTIUM TRIAL
Clinical Trial #: RTOG3510/PCORI
NCT Number: NCT02603341
Principal Investigator: Dr. Thukral
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Clinical Trial #: CCTG MA.39
NCT Number: NCT03488693
Principal Investigator: Dr. Thukral
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Randomized phase II study of elacestrant vs elacestrant plus a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) in patients with ER+/HER2- advanced or metastatic breast cancer with prior exposure to a CKD4/6 inhibitor
Clinical Trial #: NU 23B05
NCT #: NCT06062498
Principal Investigator: Dr. Gradishar
Contact: Research Office 630.933.7820

Study: A Single-Arm, Phase II Study of Autophagy Modulation using Hydroxychloroquine in combination with Encorafenib and Cetuximab or Panitumumab in Metastatic BRAF-mutated Colorectal Cancer Refractory to Standard Therapies
Clinical Trial #: NU 22I05
NCT #: NCT05576896
Principal Investigator: Dr. Mahalingam
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Clinical Trial #: NRG-GI008
NCT Number: NCT05174169
Principal Investigator: Dr. Mary Mulcahy
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response and Disease-free Survival in Patients with Locally Advanced Rectal Cancer
Clinical Trial #: A022104
NCT #: NCT05610163
Principal Investigator: Dr. Benson III
Contact: Research Office 630.933.7820

Study: A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)
Clinical Trial #: EA2183
NCT#: NCT04248452
Principal Investigator: Dr. Mihalcik
Contact: Research Office 630.933.7820

Study: Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Clinical Trial #: NRG GI006
NCT Number: NCT03801876
Principal Investigator: Dr. Mihalcik
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial
Clinical Trial #: EA2197
NCT#: NCT04559139
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Renal

Study: (PDIGEE) PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer
Clinical Trial #: A031704
NCT Number: NCT03793166
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)
Clinical Trial #: NRG-GU012
NCT Number: NCT05327686
Principal Investigator: Dr. Sean Sachdev
Contact: Research Office (630) 933-7820

Learn more at Clinicaltrials.gov

Please check back

Study: Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer
Clinical Trial #: LU008
NCT Number: NCT05624996
Principal Investigator: Dr. Abazeed
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib with or Without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)
Clinical Trial #: S1900G
NCT Number: NCT05642572
Principal Investigator: Young Chae, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Clinical Trial #: A082002
NCT Number: NCT04929041
Principal Investigator: Young Chae, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
Clinical Trial #: S2302
NCT Number: NCT05633602
Principal Investigator: Young Chae, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Clinical Trial #: EA3191
NCT Number: NCT04671667
Principal Investigator: Dr. Jochen Lorch
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Clinical Trial #: A151216
NCT Number: NCT02194738
Principal Investigator: Dr. Ferris
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Solid Tumors

Study: The OncoSET Program Database and Biobank -Combining Clinical Outcomes with Next Generation Sequencing and other Advanced Molecular Testing for Genetic Aberrations in Patients with Advanced Solid Malignancies
Clinical Trial #: NUDB 16Z01 (OncoSET)
Principal Investigator: David Vanderweele, MD
Contact: Research Office 630.933.7820

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Study: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer
Clinical Trial #: EAY191 (ComboMATCH)
NCT #: NCT05564377
Principal Investigator: Devalingam Mahalingam, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Other

Study: Randomized Phase 2 Study of Nivolumab and Ipilimumab with or Without Cabozantinib in Patients with Advanced Nasopharyngeal Carcinoma That Have Progressed After Platinum Treatment and Immunotherapy
Clinical Trial #: A092105
NCT #: NCT06010095
Principal Investigator: Dr. Lorch
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Other

Study: Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients treated with Radiation Therapy
Clinical Trial #: NU MGH13Z01
Principal Investigator: William Hartsell, MD
Contact: Research Office 630.933.7820

Other

Study: Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
Clinical Trial #: S2012
NCT #: NCT05058651
Principal Investigator: Mary F. Mulcahy, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Sarcomatoid Mesothelioma

Study: Multimodality Therapy with Immunotherapy in Stage I-IIIA Sarcomatoid Mesothelioma
Clinical Trial #: A082101
NCT #: NCT05647265
Principal Investigator: Young Chae, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov 

Oropharyngeal

Study: SPECT-CT Guided Elective Contralateral Neck Treatment [SELECT] for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial
Clinical Trial #: CCTG HN11
NCT #: NCT05451004
Principal Investigator: Katelyn Stepan, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Germ Cell Tumors

Study: A Prospective Observational Cohort Study to Assess mRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Clinical Trial #: S1823
NCT #: NCT04435756
Principal Investigator: Dr. Kundu
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Squamous Cell Carcinoma

Study: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Clinical Trial #: EA3191
NCT #: NCT04671667
Principal Investigator: Jochen Lorch, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Multiple Myeloma

Study: Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation
Clinical Trial #: EAA181
NCT Number: NCT04566328
Principal Investigator: Dr. Eisner
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Pediatric Proton Consortium Registry (PPCR)

Study: A multi-center registry of pediatric patients treated with proton radiation therapy.
Clinical Trial #: 12-103
Principal Investigator: William Hartsell, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Registry

Study: Evaluation tracking project: a prospective chart review of patients treated with proton therapy.
Clinical Trial #: REG001-09
Principal Investigator: William Hartsell, MD

Learn more at Clinicaltrials.gov

Cross-disease sites

Study: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
Clinical Trial #: MTG
Principal Investigator: Dr. Abad

Study: Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
Clinical Trial #: S2104
NCT #: NCT05040360
Principal Investigator: Dr. Mulcahy
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Clinical Trial #: A021806
NCT Number: NCT04340141
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Phase II Trial of Escalated Dose Proton Radiotherapy with Elective Nodal Irradiation and Concomitant Chemotherapy for Patients with Unresectable, Borderline Resectable or Medically Inoperable Pancreatic Adenocarcinoma
Clinical Trial #: PAN009-18
NCT Number: NCT02598349
Principal Investigator: Dr. Mohammed
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Evaluating the Response to Neoadjuvant Chemotherapy with Circulating Tumor DNA in Pancreatic Cancer
Clinical Trial #: ctDNA
NCT Number: NCT04616131
Principal Investigator: Dr. Chawla
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
Clinical Trial #: A022001
NCT #: NCT05247905
Principal Investigator: Dr. Benson III
Contact: Research Office 630.933.7820

Study: A Phase III Study of Cabazitaxel with or Without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature
Clinical Trial #: S2312
NCT #: NCT06470243
Principal Investigator: Maha Hussain, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
Clinical Trial #: DRUG CURLU177PSM0001
NCT #: NCT05204927
Principal Investigator: David Vanderweele, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: A Randomized Phase II study of ADT + Abiraterone versus ADT + Docetaxel + Abiraterone in Patients with Low Volume Metastatic Hormone Sensitive Prostate Cancer
Clinical Trial #: NU 23U08
NCT #: NCT06060587
Principal Investigator: Sarah E. Fenton, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
Clinical Trial #: PCG-GU010-18
NCT #: NCT00969111
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)
Clinical Trial #: NRG-GU009
NCT#: NCT04513717
Principal Investigator: Dr. Sean Sachdev
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Phase III Study of Image Guided Radiation Therapy with or without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
Clinical Trial #: GU003-10
NCT#: NCT01492972
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)
Clinical Trial #: NRG-GU010
NCT#: NCT05050084
Principal Investigator: Sean Sachdev
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: Phase III Study of Local or Systemic Therapy INtensification DIrected in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Clinical Trial #: EA8191
NCT#: NCT04423211
Principal Investigator: Dr. Hartsell
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: (IRONMAN) International Registry for Men with Advanced Prostate Cancer.
Clinical Trial #: c16-170
NCT Number: NCT03151629
Principal Investigator: Dr. George
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Study: The Phase III 'High Five Trial' Five Fraction Radiation For High-Risk Prostate Cancer
Clinical Trial #: NRG-GU013
NCT #: NCT05946213
Principal Investigator: Dr. Sachdev
Contact: Research Office 630.933.7820

Study: Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Clinical Trial #: S2015
Principal Investigator: Dr. Wayne
Contact: Research Office 630.933.7820

Endometrial

Study: A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Clinical Trial #: GY018
NCT #: NCT03914612
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Endometrial

Study: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma.
Clinical Trial #: NRG-GY026
NCT #: NCt05256225
Principal Investigator: Emily Hinchcliff
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Endometrial

Study: A Phase III Trial Of The Impact Of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction In Endometrial Cancer
Clinical Trial #: NRG-CC010
NCT #: NCT05646316
Principal Investigator: Dr. Hinchchiff
Contact: Research Office 630.933.7820

Ovarian

Study: Multicenter, open-label, phase 2 study of carboplatin plus mirvetuximab soravtansine followed by mirvetuximab soravtansine continuation in folate receptor-alpha positive, recurrent platinum-sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers following 1 prior line of platinum-based chemotherapy
Clinical Trial #: DRUG IMGN853-0420
NCT #: NCT05456685
Principal Investigator: Dario Roque, MD
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Ovarian

Study: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]
Clinical Trial #: NRG-CC008
NCT #: NCT04251052
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov

Ovarian or Peritoneum

Study: A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Clinical Trial #: NRG-GY019
NCT Number: NCT04095364
Principal Investigator: Dr. Alter
Contact: Research Office 630.933.7820

Learn more at Clinicaltrials.gov